Dupilumab for COPD | NEJM

293

2023-12-5 17:11

0 bullet chats

Unauthorized reproduction is prohibited

Some patients with COPD have type 2 inflammation, which may increase exacerbation risk. Dupilumab, a monoclonal antibody, targets type 2 inflammatory cytokines. New research findings are summarized in a short video. To see the full article, follow this link: https://nej.md/3Mkskdy

Comments 0

Please to post a comment~

NEJM_Group

DRLv2